What is Lantern Pharma?
Lantern Pharma Inc. is a biotechnology company dedicated to revolutionizing drug development through advanced technologies such as artificial intelligence, machine learning, and genomic data analysis. The company's product portfolio includes LP-300, currently in Phase 2 trials for non-small cell lung cancer; LP-184, in Phase 1 trials for various solid tumors and central nervous system cancers; and LP-284, also in Phase 1 trials for non-Hodgkin's lymphomas. Additionally, Lantern Pharma is developing STAR-001 for rare pediatric diseases and an antibody-drug conjugate (ADC) program. Its proprietary AI platform, RADR, enhances drug discovery and development by analyzing vast datasets. The company has also established a strategic collaboration with Oregon Therapeutics to optimize a novel protein disulfide isomerase inhibitor drug candidate.
How much funding has Lantern Pharma raised?
Lantern Pharma has raised a total of $3.7M across 1 funding round:
Series A
$3.7M
Series A (2017): $3.7M with participation from GPG Ventures and Bios Partners
Key Investors in Lantern Pharma
GPG Ventures
GPG Ventures is a Dallas-based venture capital firm with extensive operational and financial experience, specializing in investment opportunities within medical-related startups. They typically invest between $500,000 and $2,000,000, supporting companies with innovative management teams and strong growth potential in the healthcare sector.
Bios Partners
Bios Partners is a venture capital firm focused on advancing biotech innovations, particularly in the Central U.S. They invest in compelling scientific opportunities, including clinical-stage companies developing novel therapeutics for cancer and neurodegenerative disorders, leveraging their deep experience in drug development and finance.
What's next for Lantern Pharma?
With its recent major strategic investment and a robust pipeline of AI-driven drug candidates, Lantern Pharma is poised for significant advancements. The company's focus on streamlining the drug development process through technology positions it to address unmet needs in oncology and rare diseases. Future endeavors will likely concentrate on advancing its clinical-stage assets through further trials, expanding its AI platform's capabilities, and potentially forging new strategic partnerships to accelerate the commercialization of its innovative therapies. The company's commitment to data-driven drug discovery signals a forward-thinking approach in the competitive pharmaceutical landscape.
See full Lantern Pharma company page
